Portal de Periódicos da CAPES

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

2018; Massachusetts Medical Society; Volume: 378; Issue: 18 Linguagem: Inglês

10.1056/nejmoa1713901

1533-4406

David A. Lipson, Frank Barnhart, Noushin Brealey, Jean Brooks, Gerard J. Criner, Nicola C. Day, Mark T. Dransfield, David Halpin, MeiLan K. Han, Christine Jones, Sally Kilbride, Peter Lange, David A. Lomas, Fernando J. Martínez, Dave Singh, Maggie Tabberer, Robert A. Wise, Steven Pascoe,

Respiratory Support and Mechanisms

The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA), as compared with dual therapy (either inhaled glucocorticoid–LABA or LAMA–LABA), are uncertain.